Genetic and epigenetic disease modifiers in an Italian C9orf72 family expressing ALS, FTD or PD clinical phenotypes

References

• Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257–68.
   PubMed Web of Science ®Google Scholar
• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245–56.
   PubMed Web of Science ®Google Scholar
• Beck J, Poulter M, Hensman D, Rohrer JD, Mahoney CJ, Adamson G, et al. Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet. 2013;92:345–53.
   PubMed Web of Science ®Google Scholar
• Fournier C, Barbier M, Camuzat A, Anquetil V, Lattante S, Clot F, et al. Relations between C9orf72 expansion size in blood, age at onset, age at collection and transmission across generations in patients and presymptomatic carriers. Neurobiol Aging. 2019;74:234.e1–234.e8.
   Web of Science ®Google Scholar
• Gijselinck I, Van Mossevelde S, van der Zee J, Sieben A, Engelborghs S, De Bleecker J, et al. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. Mol Psychiatry. 2016;21:1112–24.
   PubMed Web of Science ®Google Scholar
• Esselin F, Mouzat K, Polge A, Juntas-Morales R, Pageot N, De la Cruz E, et al. Clinical phenotype and inheritance in patients with C9ORF72 hexanucleotide repeat expansion: results from a large French cohort. Front Neurosci 2020;14:316.
   PubMed Web of Science ®Google Scholar
• Jackson JL, Finch NCA, Baker MC, Kachergus JM, Dejesus-Hernandez M, Pereira K, et al. Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers. Mol Neurodegener 2020;15:7.
   PubMed Web of Science ®Google Scholar
• Van Mossevelde S, van der Zee J, Cruts M, Van Broeckhoven C. Relationship between C9orf72 repeat size and clinical phenotype. Curr Opin Genet Dev. 2017;44:117–24.
   PubMed Web of Science ®Google Scholar
• van der Zee J, Gijselinck I, Dillen L, Van Langenhove T, Theuns J, Engelborghs S, et al. A Pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat. 2013;34:363–73.
   PubMed Web of Science ®Google Scholar
• O'Brien M, Burke T, Heverin M, Vajda A, McLaughlin R, Gibbons J, et al. Clustering of neuropsychiatric disease in first-degree and second-degree relatives of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2017;74:1425–30.
   PubMed Web of Science ®Google Scholar
• Calvo A, Moglia C, Canosa A, Cistaro A, Valentini C, Carrara G, et al. Amyotrophic lateral sclerosis/frontotemporal dementia with predominant manifestations of obsessive-compulsive disorder associated to GGGGCC expansion of the c9orf72 gene. J Neurol. 2012;259:2723–5.
   PubMed Web of Science ®Google Scholar
• Floris G, Borghero G, Cannas A, Di Stefano F, Costantino E, Murru MR, et al. Frontotemporal dementia with psychosis, parkinsonism, visuo-spatial dysfunction, upper motor neuron involvement associated to expansion of C9ORF72: a peculiar phenotype? J Neurol. 2012;259:1749–51.
   PubMed Web of Science ®Google Scholar
• Cooper-Knock J, Kirby J, Highley R, Shaw PJ. The spectrum of C9orf72-mediated neurodegeneration and amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12:326–39.
   PubMed Web of Science ®Google Scholar
• Saracino D, Le Ber I. Clinical update on C9orf72: frontotemporal dementia, amyotrophic lateral sclerosis, and beyond. Adv Exp Med Biol. 2021;1281:67–76.
   PubMed Web of Science ®Google Scholar
• Van Blitterswijk M, Van Es MA, Hennekam EAM, Dooijes D, Van Rheenen W, Medic J, et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet. 2012;21:3776–84.
   PubMed Web of Science ®Google Scholar
• Morgan S, Shatunov A, Sproviero W, Jones AR, Shoai M, Hughes D, et al. A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK. Brain. 2017;140:1611–8.
   PubMed Web of Science ®Google Scholar
• Ross JP, Leblond CS, Laurent SB, Spiegelman D, Dionne-Laporte A, Camu W, et al. Oligogenicity, C9orf72 expansion, and variant severity in ALS. Neurogenetics 2020;21:227–42.
   PubMed Web of Science ®Google Scholar
• McCann EP, Henden L, Fifita JA, Zhang KY, Grima N, Bauer DC, et al. Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. J Med Genet 2021;58:87–95.
   Web of Science ®Google Scholar
• Corrado L, Tiloca C, Locci C, Bagarotti A, Hamzeiy H, Colombrita C, et al. Characterization of the c9orf72 GC-rich low complexity sequence in two cohorts of Italian and Turkish ALS cases. Amyotroph Lateral Scler Front Degener 2018;19:426–431.
   PubMed Web of Science ®Google Scholar
• Xi Z, Zinman L, Moreno D, Schymick J, Liang Y, Sato C, et al. Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am J Hum Genet. 2013;92:981–9.
   PubMed Web of Science ®Google Scholar
• Russ J, Liu EY, Wu K, Neal D, Suh ER, Irwin DJ, et al. Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. Acta Neuropathol. 2015;129:39–52.
   PubMed Web of Science ®Google Scholar
• Xi Z, Rainero I, Rubino E, Pinessi L, Bruni AC, Maletta RG, et al. Hypermethylation of the CpG-island near the C9orf72 G4C2-repeat expansion in FTLD patients. Hum Mol Genet. 2014;23:5630–7.
   PubMed Web of Science ®Google Scholar
• Belzil VV, Bauer PO, Gendron TF, Murray ME, Dickson D, Petrucelli L. Characterization of DNA hypermethylation in the cerebellum of c9FTD/ALS patients. Brain Res. 2014;1584:15–21.
   PubMed Web of Science ®Google Scholar
• Liu EY, Russ J, Wu K, Neal D, Suh E, McNally AG, et al. C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. Acta Neuropathol. 2014;128:525–41.
   PubMed Web of Science ®Google Scholar
• McMillan CT, Russ J, Wood EM, Irwin DJ, Grossman M, McCluskey L, et al. C9orf72 promoter hypermethylation is neuroprotective: neuroimaging and neuropathologic evidence. Neurology 2015;84:1622–30.
   PubMed Web of Science ®Google Scholar
• Akimoto C, Volk AE, van Blitterswijk M, Van den Broeck M, Leblond CS, Lumbroso S, et al. A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. J Med Genet. 2014;51:419–24.
   PubMed Web of Science ®Google Scholar
• Dols-Icardo O, García-Redondo A, Rojas-García R, Sánchez-Valle R, Noguera A, Gó mez-Tortosa E, et al. Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. Hum Mol Genet. 2014;23:749–54.
   PubMed Web of Science ®Google Scholar
• van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, Murray ME, Heckman MG, Diehl NN, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol. 2013;12:978–88.
   PubMed Web of Science ®Google Scholar
• Nordin A, Akimoto C, Wuolikainen A, Alstermark H, Jonsson P, Birve A, et al. Extensive size variability of the GGGGCC expansion in C9orf72 in both neuronal and non-neuronal tissues in 18 patients with ALS or FTD. Hum Mol Genet. 2015;24:3133–42.
   PubMed Web of Science ®Google Scholar
• Suh ER, Lee EB, Neal D, Wood EM, Toledo JB, Rennert L, et al. Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathol. 2015;130:363–72.
   PubMed Web of Science ®Google Scholar
• Van Mossevelde S, Van Der Zee J, Gijselinck I, Sleegers K, De Bleecker J, Sieben A, et al. Clinical evidence of disease anticipation in families segregating a C9orf72 repeat expansion. JAMA Neurol. 2017;74:445–52.
   PubMed Web of Science ®Google Scholar
• Ramirez A, Heimbach A, Gründemann J, Stiller B, Hampshire D, Cid LP, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006;38:1184–91.
   PubMed Web of Science ®Google Scholar
• Park JS, Blair NF, Sue CM. The role of ATP13A2 in Parkinson's disease: clinical phenotypes and molecular mechanisms. Mov Disord. 2015;30:770–9.
   PubMed Web of Science ®Google Scholar
• Hopfner F, Mueller SH, Szymczak S, Junge O, Tittmann L, May S, et al. Rare variants in specific lysosomal genes are associated with Parkinson's disease. Mov Disord. 2020;35:1245–8.
   PubMed Web of Science ®Google Scholar
• Djarmati A, Hagenah J, Reetz K, Winkler S, Behrens MI, Pawlack H, et al. ATP13A2 variants in early-onset Parkinson’s disease patients and controls. Mov Disord. 2009;24:2104–11.
   PubMed Web of Science ®Google Scholar
• Dehay B, Martinez-Vicente M, Ramirez A, Perier C, Klein C, Vila M, et al. Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove. Autophagy 2012;8:1389–91.
   PubMed Web of Science ®Google Scholar
• Chartier-Harlin MC, Dachsel JC, Vilariño-Güell C, Lincoln SJ, Leprêtre F, Hulihan MM, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet. 2011;89:398–406.
   PubMed Web of Science ®Google Scholar
• Deng H, Wu Y, Jankovic J. The EIF4G1 gene and Parkinson's disease. Acta Neurol Scand. 2015;132:73–8.
   PubMed Web of Science ®Google Scholar
• Saini P, Rudakou U, Yu E, Ruskey JA, Asayesh F, Laurent SB, et al. Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease. Neurobiol Aging. 2021;100:119.e7–e13.
   Web of Science ®Google Scholar